Selexis SA has entered a commercial license agreement that provides Takeda with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform. Takeda is leveraging Selexis’ mammalian cell line-based protein expression platform to develop recombinant fusion proteins. “Successfully developing a high-performance cell line expressing Takeda’s fusion proteins validates the strength of our SUREtechnology Platform,” said Yemi Onakunle, vice president, busi...